SCHEMBL1367494

SCHEMBL1367494

O=C(NC1CCN(Cc2ccccc2)CC1)c1cnc(-c2ccccc2)nc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A12 P48065 4/20 0.62
PRKAA2 P54646 4/20 0.61
PRKAB2 O43741 3/20 0.61
PRKAG1 P54619 3/20 0.61
PRKAA1 Q13131 3/20 0.61
PRKAG3 Q9UGI9 3/20 0.61
PRKAG2 Q9UGJ0 3/20 0.61
PRKAB1 Q9Y478 3/20 0.61
DRD4 P21917 3/20 0.59
SIGMAR1 Q99720 3/20 0.58
POLB P06746 1/20 0.58
SLC6A13 Q9NSD5 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
TMEM97 Q5BJF2 2/20 0.55
JAK2 O60674 1/20 0.55
JAK1 P23458 1/20 0.55
TYK2 P29597 1/20 0.55
JAK3 P52333 1/20 0.55
MCHR1 Q99705 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1366388 0.89 POLB (0.63) SLC6A12PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL1367633 0.88 DRD4 (0.61) SLC6A12PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL1365085 0.86 HPGDS (0.64) SLC6A12PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL1366639 0.85 SLC6A12 (0.57) SLC6A12DRD4POLBMEN1KMT2A
SCHEMBL1366750 0.85 CKS1B (0.47) SLC6A12PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL12141992 0.85 KMT2A (0.51) PRKAA1KMT2AJAK3MAPK1
SCHEMBL1366534 0.85 PRKAA2 (0.75) SLC6A12PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL1364727 0.82 ADORA2A (0.49) DRD4CYP3A4CYP2D6
SCHEMBL7239441 0.78 CCR3 (0.72) SLC6A12DRD4SIGMAR1POLBMEN1
SCHEMBL2073964 0.78 PRKAA2 (0.78) SLC6A12PRKAA2PRKAB2PRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions CYP11B2, CYP11B1, LTC4S SLC6A12 3147/4885PRKAA2 3883/4885PRKAB2 4386/4885
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions CYP11B2, CYP11B1, LTC4S SLC6A12 3147/4885PRKAA2 3883/4885PRKAB2 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.